托菲内提德 - - 雷特综合征治疗的新篇章
1Department of Medicine, Mayo Hospital, King Edward Medical University, Lahore, Punjab, Pakistan.
Frontiers in pharmacology
|November 30, 2023
概括
托菲尼提德是FDA批准治疗儿童雷特综合征的第一个药物. 临床研究表明,它显著改善了行为评分,为这种罕见的神经疾病提供了新的治疗选择.
科学领域:
- 神经学 神经学
- 儿科 儿科 儿科
- 药理学 药理学是指药理学的学科.
背景情况:
- 雷特综合征是一种罕见的遗传神经系统疾病,影响大脑发育.
- 目前,对雷特综合征的治疗选择有限,专注于症状管理.
研究的目的:
- 评估Trofinetide在治疗雷特综合征方面的疗效和安全性.
- 评估Trofinetide对Rett综合征的儿科患者行为症状的影响.
主要方法:
- 进行了临床试验,涉及2岁及以上的儿科患者,被诊断患有雷特综合征.
- 该研究使用雷特综合征行为问卷评估了行为改善.
- 在整个研究过程中,对安全性和不良事件进行了监测.
主要成果:
- 托菲尼提德在患有雷特综合征的患者的行为评分中显示出统计学上显著的改善.
- 药物一般耐受性很好,尽管对不良事件的进一步研究仍在进行中.
- 这标志着雷特综合征治疗选择的重大进步.
结论:
- 托菲尼提德代表了雷特综合征的一种新型治疗方法,解决了一个关键的未满足的需求.
- 药物在改善行为症状方面的有效性为改善病情提供了潜在的潜力.
- 进一步的研究是有必要的,以充分了解长期的安全性和有效性概况.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Acne Infection
Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...


